Guidant buys Cook in $3 billion stock deal
This article was originally published in Clinica
Executive Summary
Guidant is spending up to $3bn to ensure its position in the potentially huge drug-coated stent market by buying Cook Group in a stock for stock transaction. The two companies are already collaborating to develop a product, but received a severe blow in June 2002 when a US district court ruled that an agreement between them giving Guidant access to the drug paclitaxel was a "sham" (see Clinica No 1012, p 13).